FDA Accelerates PORT-77 for Rare Sunlight-Sensitive Disorders
Portal Therapeutics, in partnership with GondolaBio, has achieved a milestone with the FDA granting orphan drug and fast track status to its oral therapy candidate, PORT-77. This investigational drug, according…